MRC1 and pancreatic neoplasm: Based on our results, universal testing of pancreatic cancer patients using a panel test would identify pathogenic variants or HiP-VUS in MMR genes at a frequency similar to what is detected with universal screening of CRC patients, 1.3 and 1.2% respectively [56].